^
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: A1 - Approval
|
temozolomide Sensitive: A1 - Approval
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
temozolomide gel Sensitive: A2 - Guideline
|
temozolomide gel Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
BRAF V600
|
Astrocytoma
|
BRAF V600
|
Astrocytoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
Anaplastic Astrocytoma
|
BRAF V600
|
Anaplastic Astrocytoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRAF V600
|
Astrocytoma
|
BRAF V600
|
Astrocytoma
|
dabrafenib Sensitive: C1 - Off-label
|
dabrafenib Sensitive: C1 - Off-label
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
KIAA1549-BRAF fusion
|
Astrocytoma
|
KIAA1549-BRAF fusion
|
Astrocytoma
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
NRAS mutation
|
Anaplastic Astrocytoma
|
NRAS mutation
|
Anaplastic Astrocytoma
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
IDH2 mutation
|
Anaplastic Astrocytoma
|
IDH2 mutation
|
Anaplastic Astrocytoma
|
PCV Sensitive: C3 – Early Trials
|
PCV Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Anaplastic Astrocytoma
|
IDH1 mutation
|
Anaplastic Astrocytoma
|
PCV Sensitive: C3 – Early Trials
|
PCV Sensitive: C3 – Early Trials
|
ABCB1 G412G
|
Anaplastic Astrocytoma
|
ABCB1 G412G
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: C3 – Early Trials
|
temozolomide Sensitive: C3 – Early Trials
|
TMB-H
|
Anaplastic Astrocytoma
|
TMB-H
|
Anaplastic Astrocytoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
FGFR mutation
|
Astrocytoma
|
FGFR mutation
|
Astrocytoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR fusion
|
Astrocytoma
|
FGFR fusion
|
Astrocytoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
Astrocytoma
|
IDH1 mutation
|
Astrocytoma
|
temozolomide Sensitive: C4 – Case Studies
|
temozolomide Sensitive: C4 – Case Studies
|
NACC2-NTRK2 fusion
|
Anaplastic Astrocytoma
|
NACC2-NTRK2 fusion
|
Anaplastic Astrocytoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Astrocytoma
|
FGFR3-TACC3 fusion
|
Astrocytoma
|
ABSK091 Sensitive: C4 – Case Studies
|
ABSK091 Sensitive: C4 – Case Studies
|
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion
|
Astrocytoma
|
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion
|
Astrocytoma
|
larotrectinib Sensitive: C4 – Case Studies
|
larotrectinib Sensitive: C4 – Case Studies
|
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation
|
Anaplastic Astrocytoma
|
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation
|
Anaplastic Astrocytoma
|
carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies
|
carboplatin + temozolomide + vincristine Resistant: C4 – Case Studies
|
BRAF V600E + PIK3CA mutation
|
Astrocytoma
|
BRAF V600E + PIK3CA mutation
|
Astrocytoma
|
vemurafenib + everolimus Sensitive: C4 – Case Studies
|
vemurafenib + everolimus Sensitive: C4 – Case Studies
|
BRAF mutation
|
Anaplastic Astrocytoma
|
BRAF mutation
|
Anaplastic Astrocytoma
|
dabrafenib Sensitive: C4 – Case Studies
|
dabrafenib Sensitive: C4 – Case Studies
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
palbociclib + PLX4720 Sensitive: D – Preclinical
|
palbociclib + PLX4720 Sensitive: D – Preclinical
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
PLX4720 Sensitive: D – Preclinical
|
PLX4720 Sensitive: D – Preclinical
|
